Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 March 2009:
Vol. 323. no. 5921, pp. 1567 - 1568
DOI: 10.1126/science.1172253
Prev | Table of Contents | Next

Perspectives

IMMUNOLOGY:
Two-in-One Designer Antibodies

Paul W. H. I. Parren1 and Dennis R. Burton2

An antibody is engineered to recognize two different proteins with high affinity, opening the door to improved combination therapies for cancers and infections.

1Genmab, Yalelaan 60, 3584 CM Utrecht, Netherlands. E-mail: p.parren{at}genmab.com

2Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA. E-mail: burton{at}scripps.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Antiangiogenic Drugs: Insights into Drug Development from Endostatin, Avastin and Thalidomide.
J. W. Holaday and B. A. Berkowitz (2009)
Mol. Interv. 9, 157-166
   Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)